Correspondence 0001213900-24-107647 from MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252) (MYNZ)
MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252)
Date: Dec. 11, 2024 · CIK: 0001874252 · Accession: 0001213900-24-107647
AI Filing Summary & Sentiment
Reasoning
Letter
Mainz Biomed N.V.
Robert Koch Strasse
55129 Mainz
Germany
December 11, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Mainz Biomed N.V.
Registration Statement on Form F-1
File No. 333- 282993
Ladies and Gentlemen:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 5:00 pm Eastern Time on Thursday, December 12, 2024, or as soon thereafter as practicable.
The Company understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
The undersigned respectfully requests that it be notified of the effectiveness of the above-referenced Registration Statement by telephone call to our counsel, Ortoli Rosenstadt LLP, by calling Tim Dockery at (212) 829-8946.
Very truly yours,
MAINZ BIOMED N.V.
Show Raw Text
CORRESP
1
filename1.htm
Mainz Biomed N.V.
Robert Koch Strasse
50
55129 Mainz
Germany
December 11, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re:
Mainz Biomed N.V.
Registration
Statement on Form F-1
File No.
333- 282993
Ladies and Gentlemen:
The Company hereby requests,
pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), acceleration of the
effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 5:00 pm Eastern
Time on Thursday, December 12, 2024, or as soon thereafter as practicable.
The Company understands
that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation
of the fact that the Company is aware of its responsibilities under the Securities Act as they relate to the proposed public offering
of the securities specified in the Registration Statement.
The undersigned respectfully
requests that it be notified of the effectiveness of the above-referenced Registration Statement by telephone call to our counsel, Ortoli
Rosenstadt LLP, by calling Tim Dockery at (212) 829-8946.
Very truly yours,
MAINZ BIOMED N.V.
By:
/s/ William J. Caragol
Name:
William J. Caragol
Title:
Chief Financial Officer